View Older Stories View More Recent Stories

Nov 20, 2025 04:08PM Phio Pharmaceuticals Corp. (PHIO) files for 11.76M share offering by selling stockholders
Nov 17, 2025 08:45AM Phio Pharmaceuticals Announces Upcoming Podium Presentation at the Advanced Therapies USA 2025 Congress
Nov 13, 2025 06:33PM Phio Pharmaceuticals Corp. (PHIO) Misses Q3 EPS by 44c
Nov 13, 2025 04:15PM Phio Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
Nov 7, 2025 10:30AM Phio Pharmaceuticals to Present Recent Clinical Results from Skin Cancer Trial with siRNA based INTASYL PH-762
Nov 7, 2025 07:47AM Phio Pharmaceuticals' PH-762 wins biotech breakthrough award
Nov 7, 2025 07:45AM Phio Pharmaceuticals Announces INTASYL PH-762 is Named Immunomodulatory Solution of the Year in the BioTech Breakthrough Award Program
Nov 3, 2025 01:42PM Phio Pharmaceuticals raises $13.4 million through warrant exercises
Nov 3, 2025 01:40PM Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $13.4 Million Gross Proceeds
Nov 3, 2025 07:48AM Phio Pharmaceuticals reports positive results in skin cancer trial
Nov 3, 2025 07:45AM Phio Pharmaceuticals Announces Positive Pathology Results: Final Maximum Dose Cohort for INTASYL PH-762 Skin Cancer Trial
Oct 31, 2025 10:19AM Phio Pharmaceuticals names David Deming as lead independent director
Oct 31, 2025 10:15AM Phio Pharmaceuticals Announces Appointment of Mr. David H. Deming to the Position of Lead Independent Director
Oct 21, 2025 07:45AM Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
Sep 23, 2025 07:45AM Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
Sep 18, 2025 07:45AM Phio Pharmaceuticals to Present at the Life Sciences Future Conference
Sep 3, 2025 07:45AM Phio Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Aug 15, 2025 06:09AM Phio Pharmaceuticals Corp. (PHIO) Files for 1.93M Share Offering by Selling Stockholders
Aug 14, 2025 05:25PM Phio Pharmaceuticals Corp. (PHIO) Misses Q2 EPS by 45c
Aug 14, 2025 04:15PM Phio Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
Jul 25, 2025 03:08PM Phio Pharmaceuticals raises $2.5 million through warrant exercise
Jul 25, 2025 03:04PM Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $2.5 Million Gross Proceeds
Jul 25, 2025 12:46PM Phio Pharmaceuticals reports complete response in skin cancer trial
Jul 25, 2025 12:36PM Phio Pharmaceuticals Announces Pathology Results for Four of Five Patients in Fourth Cohort
Jul 25, 2025 07:47AM Phio Pharmaceuticals signs manufacturing deal for PH-762 drug substance
Jul 25, 2025 07:45AM Phio Pharmaceuticals Announces Agreement with U.S. Manufacturing Source for Drug Substance
Jun 26, 2025 06:46AM H.C. Wainwright Reiterates Buy Rating on Phio Pharma (PHIO)
Jun 25, 2025 07:47AM Phio Pharmaceuticals Corp. (PHIO) Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Clinical Trial to Fifth Dose Escalation Cohort
Jun 25, 2025 07:45AM Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Clinical Trial to Fifth Dose Escalation Cohort
Jun 24, 2025 07:45AM Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
Jun 6, 2025 07:48AM Phio Pharmaceuticals Corp. (PHIO) Announces Strategic Initiative to Create Awareness of the INTASYL siRNA Portfolio
Jun 6, 2025 07:45AM Phio Pharmaceuticals Announces Strategic Initiative to Create Awareness of the Comprehensive INTASYL siRNA Portfolio
Jun 5, 2025 06:08AM H.C. Wainwright Assumes Phio Pharma (PHIO) at Buy
May 19, 2025 07:45AM Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference
May 15, 2025 06:51PM Phio Pharmaceuticals Corp. (PHIO) Misses Q1 EPS by 41c
May 15, 2025 04:15PM Phio Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
May 7, 2025 07:47AM Phio Pharmaceuticals (PHIO) Announces Positive Pathology Results in Third Cohort in INTASYL PH-762 Skin Cancer Clinical Trial
May 7, 2025 07:45AM Phio Pharmaceuticals Announces Positive Pathology Results in Third Cohort in INTASYL PH-762 Skin Cancer Clinical Trial
May 1, 2025 07:45AM Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
Apr 9, 2025 07:47AM Phio Pharmaceuticals Corp. (PHIO) Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Study to Fourth Dose Escalation Cohort
Apr 9, 2025 07:45AM Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Study to Fourth Dose Escalation Cohort
Apr 8, 2025 06:47AM H.C. Wainwright Reiterates Buy Rating on Phio Pharma (PHIO)
Apr 3, 2025 07:45AM Phio Pharmaceuticals Announces Podium Presentations on INTASYL siRNA Lead Product Candidates PH-762 and PH-894
Mar 31, 2025 04:00PM Phio Pharmaceuticals Reports 2024 Year End Financial Results and Provides Business Update
Mar 10, 2025 07:45AM American Academy of Dermatology Awards Podium Presentation to Phio Pharmaceutical's Clinical Research at 2025 Annual Meeting
Mar 5, 2025 07:45AM Phio Pharmaceuticals Announces Completion of Enrollment in Third Safety Cohort in PH-762 Phase 1b Dose-Escalation Study
Feb 26, 2025 07:45AM Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
Feb 20, 2025 07:48AM Phio Pharmaceuticals Corp. (PHIO) Appoints David H. Deming to its Board
Feb 20, 2025 07:45AM Phio Pharmaceuticals Announces Appointment of David H. Deming to Board of Directors
Feb 20, 2025 06:54AM H.C. Wainwright Reiterates Buy Rating on Phio Pharma (PHIO)
View More Recent Stories View Older Stories